IVERIC bio, Inc.
ISEEDelisted Jul 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001410939
IVERIC bio, Inc. was delisted on Jul 11, 2023; its insiders filed their last Form 4 on Jul 13, 2023; 256 institutions reported holding it in 13F filings for Q2 2023, worth $5.33B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:03 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2023 | Feb 24, 2022 | Jan 11, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Revenue | – | – | – | $0 | $0 |
| Operating expenses | $189.9M | $114.8M | $88.7M | $61.3M | $65.3M |
| Research and development | $117.0M | $85.1M | $62.8M | $39.6M | $41.7M |
| Selling, general and administrative | $72.9M | $29.7M | $26.0M | $21.6M | $23.6M |
| Operating income | -$189.9M | -$114.8M | -$88.7M | -$61.3M | -$65.3M |
| Income tax | $0 | $0 | -$3.69M | -$111.0K | -$1.06M |
| Net income | -$185.2M | -$114.5M | -$84.5M | -$58.9M | $63.1M |
| EPS, basic | $-1.53 | $-1.12 | $-1.14 | $-1.39 | $1.70 |
| EPS, diluted | $-1.53 | $-1.12 | $-1.14 | $-1.39 | $1.70 |
| Weighted shares, basic | 121.0M | 101.9M | 74.2M | 42.2M | 37.1M |
| Weighted shares, diluted | 121.0M | 101.9M | 74.2M | 42.2M | 37.1M |
| Margins and growth | |||||
| Net income growth, year over year | – | – | – | −193.3% | −44.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2023 | Feb 24, 2022 | Jan 11, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Cash and equivalents | $476.3M | $261.4M | $66.4M | $125.7M | $131.2M |
| Total current assets | $662.8M | $387.5M | $216.6M | $128.6M | $133.3M |
| Property, plant and equipment | $946.0K | $348.0K | $26.0K | $173.0K | $335.0K |
| Total assets | $666.8M | $389.4M | $216.8M | $130.2M | $137.2M |
| Total current liabilities | $35.6M | $28.2M | $25.1M | $13.0M | $13.2M |
| Long-term debt | $96.6M | – | – | – | – |
| Total liabilities | $132.2M | $28.8M | $25.2M | $13.0M | $13.2M |
| Shareholders' equity | $534.7M | $360.5M | $191.6M | $117.2M | $124.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2023 | Feb 24, 2022 | Jan 11, 2021 | Jan 13, 2020 | Jan 7, 2019 |
| Operating cash flow | -$163.8M | -$98.6M | -$66.1M | -$48.5M | -$41.9M |
| Capital expenditures | $736.0K | $361.0K | – | – | $0 |
| Free cash flow | -$164.5M | -$98.9M | – | – | -$41.9M |
| Stock-based compensation | $26.7M | $11.2M | $8.32M | $9.18M | $11.1M |
| Investing cash flow | -$50.3M | $21.3M | -$143.8M | $150.0K | $0 |
| Financing cash flow | $428.9M | $272.3M | $150.6M | $42.8M | $6.14M |
| Net change in cash | $214.9M | $195.1M | -$59.3M | -$5.50M | -$35.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 1, 2023 | 137.8M | +18.4% | SEC |
| Feb 27, 2023 | 137.1M | +18.5% | SEC |
| Oct 31, 2022 | 120.7M | +5.3% | SEC |
| Jul 22, 2022 | 118.1M | +13.5% | SEC |
| May 2, 2022 | 116.4M | +29.0% | SEC |
| Feb 21, 2022 | 115.7M | +28.3% | SEC |
| Nov 5, 2021 | 114.6M | +28.0% | SEC |
| Jul 30, 2021 | 104.0M | +16.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.